Table 2

IR and HR of composite serious infections in tocilizumab initiators vs TNFi, propensity score-matched with a 1:3 variable ratio

TocilizumabTNFiHR (95% CI)Rate difference†
Subjects (n)EventsPerson-yearsIR* (95% CI)Subjects (n)EventsPerson-yearsIR* (95% CI)
As-treated analysis
 Medicare582734148407.05 (6.30 to 7.79)10 71666291937.20 (6.65 to 7.75)0.94 (0.82 to 1.07)−0.15 (−1.08, 0.78)
 IMS464214741303.56 (2.98 to 4.13)10 33324998602.53 (2.21 to 2.84)1.30 (1.05 to 1.61)1.03 (0.37, 1.69)
 MarketScan560513042283.07 (2.55 to 3.60)12 06024498972.47 (2.16 to 2.77)1.16 (0.93 to 1.44)0.60 (−0.01, 1.21)
 Combined16 07461813 1984.68 (4.31 to 5.05)33 109115528 9503.99 (3.76 to 4.22)1.05 (0.95 to 1.16)0.69 (0.25, 1.13)
Intention-to-treat analysis up to 180 days
 Medicare582722626388.57 (7.45 to 9.68)10 71640748158.45 (7.63 to 9.27)0.98 (0.83 to 1.16)0.12 (−1.27, 1.51)
 IMS46429121314.27 (3.39 to 5.15)10 33315047403.16 (2.66 to 3.67)1.22 (0.94 to 1.60)1.11 (0.1, 2.12)
 MarketScan56058324453.39 (2.66 to 4.13)12 06013652602.59 (2.15 to 3.02)1.26 (0.95 to 1.66)0.80 (−0.05, 1.65)
 Combined16 07440072145.54 (5.00 to 6.09)33 10969314 8154.68 (4.33 to 5.03)1.04 (0.91 to 1.20)0.86 (0.21, 1.51)
  • *Incidence rate (IR) is per 100 person-years.

  • †Rate difference per 100 patients (tocilizumab-TNFi).

  • TNFi, tumour necrosis factor inhibitors.